Biomedicine · global
Low-Cost Older Drug Challenges Standard Multiple Sclerosis Treatment, Nordic Trial Provides Direct Comparative Evidence
A Norwegian and Swedish clinical trial shows that rituximab’s efficacy and safety in newly diagnosed relapsing multiple sclerosis may be no worse than those of the more expensive ocrelizumab; this is not only a question of drug choice, but also affects whether early high-efficacy treatment can become affordable for more people.
Treatment for multiple sclerosis has increasingly emphasized using high-efficacy drugs early in the disease course in recent years, aiming to minimize relapses and the accumulation of neurological damage. But high efficacy does not often mean accessibility, and price often draws a line for many patients and healthcare systems first. Now, a Nordic clinical trial has focused on a simple but pointed question: if a less expensive B-cell-depleting therapy can achieve similar results, should the cost logic of standard treatment also be re-examined?
According to Medical Xpress, the OVERLORD-MS trial, published in the New England Journal of Medicine, compared the performance of rituximab and ocrelizumab in patients with newly diagnosed relapsing multiple sclerosis. The study, conducted jointly in Norway and Sweden, used a randomized, double-blind, head-to-head design, with participants followed for 30 months and assessed using magnetic resonance imaging and clinical indicators.
Both drugs primarily target B cells. Ocrelizumab is already a common high-efficacy therapy in multiple sclerosis treatment; rituximab was developed earlier and is commonly used for other immune and blood disorders, and it has also accumulated clinical experience in multiple sclerosis in some regions. The importance of this study lies in the fact that it is not simply an inference from real-world data, but a direct, blinded randomized comparison in early-stage patients.
The report noted that the trial results showed rituximab was comparable to ocrelizumab in efficacy and safety. If this conclusion holds up in different healthcare settings, the impact will go beyond a single prescribing choice: for public healthcare systems under heavy budget pressure, lower cost may allow more patients to receive high-efficacy treatment early; for low- and middle-income regions, it may narrow the accessibility gap for modern treatment.
However, this study also needs to be understood within its boundaries. The source summary did not provide the full number of participants, primary endpoint values, details of various adverse events, or subgroup analyses, so “comparable” cannot be interpreted as unconditional substitution for all patients and all stages of disease. Treatment choices must still take into account approved indications, administration procedures, infection-risk monitoring, insurance, and local medical regulations.
This trial is also connected to research into the causes of multiple sclerosis. Biological materials collected in the study will be used to explore how B-cell depletion affects immune mechanisms related to Epstein-Barr virus; EBV has in recent years been regarded as one of the key clues in research on multiple sclerosis risk. In other words, this comparative trial not only answers “which drug has a similar effect,” but may also help explain why regulating B cells can alter disease activity.
For clinical practice, perhaps the most pragmatic message is this: high-quality comparative trials supported by academic and public funding can still raise weighty questions in a treatment landscape dominated by expensive new drugs. Whether rituximab will therefore change treatment guidelines in more countries will depend on the complete data, regulatory attitudes, and healthcare reimbursement decisions; but it has already moved the discussion of multiple sclerosis treatment one step away from simply pursuing new drugs and toward a balance among efficacy, cost, and equity.